Rapid dFLC Response Predict CHR in AL Amyloidosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rapid dFLC Response Predict CHR in AL Amyloidosis — Stella

Recruiting

Back to Systemic AL Amyloidosis trials

Trial locations(8 sites)

China

Peking University People's Hospital, Beijing, Beijing Municipality

Fuxing Hospital affiliated to Capital Medical University, Beijing, Beijing Municipality

Beijing Anzhen Hospital, Beijing, Beijing Municipality

Peking University First Hospital, Beijing, Beijing Municipality

First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang

Key details

Sponsor

Peking University People's Hospital

Enrollment target

~50 participants

Started

October 2024

Primary completion

June 2026

Age range

18 Years – 99 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov